JHL Biotech Reports Randomization of Patients in P-III Study of JHL1101 for Diffuse Large B-Cell Lymphoma

 JHL Biotech Reports Randomization of Patients in P-III Study of JHL1101 for Diffuse Large B-Cell Lymphoma

JHL Biotech Reports Randomization of Patients in P-III Study of JHL1101 for Diffuse Large B-Cell Lymphoma

Shots:
 
  • The study involves assessing of JHL1101 + CHOP (J-CHOP) vs rituximab + CHOP (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma
  •  Post P-III Study of JHL1101 and combination therapy, JHL Biotech plans to conduct PK study in RA patients in EU
  • JHL1101 (biosimilar to Rituximab) is a mAb targeting CD20 cells, for non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and rheumatoid arthritis (RA)

Click here to read full press release/ article | Ref: PRNewswire   | Image: Asian Scientist Magazine

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post